[go: up one dir, main page]

MX2019013291A - Compuestos y metodos para tratar infecciones bacterianas. - Google Patents

Compuestos y metodos para tratar infecciones bacterianas.

Info

Publication number
MX2019013291A
MX2019013291A MX2019013291A MX2019013291A MX2019013291A MX 2019013291 A MX2019013291 A MX 2019013291A MX 2019013291 A MX2019013291 A MX 2019013291A MX 2019013291 A MX2019013291 A MX 2019013291A MX 2019013291 A MX2019013291 A MX 2019013291A
Authority
MX
Mexico
Prior art keywords
compounds
methods
bacterial infections
treat bacterial
formula
Prior art date
Application number
MX2019013291A
Other languages
English (en)
Other versions
MX385203B (es
Inventor
Zhang Jing
Guler Satenig
Tommasi Ruben
Romero Jan
Wu Xiaoyun
Comita - Prevoir Janelle
Francois Durand - Reville Thomas
Sylvester Mark
Velez - Vega Camilo
Original Assignee
Entasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Inc filed Critical Entasis Therapeutics Inc
Publication of MX2019013291A publication Critical patent/MX2019013291A/es
Publication of MX385203B publication Critical patent/MX385203B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se proporcionan compuestos antibacterianos representados por la Formula I,(I); o una sal farmaceuticamente aceptable del mismo, en donde X, Y, R4, R5 y R6 son como se definen en la presente. Tambien se proporcionan composiciones farmaceuticas que comprenden los compuestos de Formula I.
MX2019013291A 2017-05-08 2018-05-08 Compuestos y métodos para tratar infecciones bacterianas. MX385203B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502867P 2017-05-08 2017-05-08
PCT/US2018/031593 WO2018208769A1 (en) 2017-05-08 2018-05-08 Compounds and methods for treating bacterial infections

Publications (2)

Publication Number Publication Date
MX2019013291A true MX2019013291A (es) 2020-01-15
MX385203B MX385203B (es) 2025-03-14

Family

ID=62223332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013291A MX385203B (es) 2017-05-08 2018-05-08 Compuestos y métodos para tratar infecciones bacterianas.

Country Status (27)

Country Link
US (1) US11046694B2 (es)
EP (1) EP3630111B1 (es)
JP (1) JP7058322B2 (es)
KR (1) KR102611447B1 (es)
CN (1) CN110709081B (es)
AU (1) AU2018266640B2 (es)
CY (1) CY1125340T1 (es)
DK (1) DK3630111T3 (es)
EA (1) EA038393B1 (es)
ES (1) ES2907858T3 (es)
HR (1) HRP20220231T1 (es)
HU (1) HUE057592T2 (es)
IL (1) IL270380B (es)
LT (1) LT3630111T (es)
MA (1) MA48743A (es)
MX (1) MX385203B (es)
MY (1) MY201377A (es)
NZ (1) NZ758200A (es)
PE (1) PE20200333A1 (es)
PH (1) PH12019502509A1 (es)
PL (1) PL3630111T3 (es)
PT (1) PT3630111T (es)
SG (1) SG11201909443YA (es)
SI (1) SI3630111T1 (es)
SM (1) SMT202200110T1 (es)
TW (1) TWI791018B (es)
WO (1) WO2018208769A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110111A1 (en) 2018-08-09 2020-02-13 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
WO2022233181A1 (en) 2021-05-07 2022-11-10 Ningxia Academy Of Agriculture And Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
US11814385B2 (en) 2021-06-25 2023-11-14 University Of South Florida Small molecule inhibitors targeting Clostridioides difficile sporulation
WO2025064681A1 (en) * 2023-09-19 2025-03-27 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
RU2560846C1 (ru) 2011-07-26 2015-08-20 Вокхардт Лимитед Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
KR101738210B1 (ko) 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
PT2872510T (pt) * 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
WO2013122888A2 (en) 2012-02-15 2013-08-22 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8933232B2 (en) 2012-03-30 2015-01-13 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
KR101946107B1 (ko) 2012-08-25 2019-02-08 욱크하르트 리미티드 １,６-디아자비시클로〔３,２,１〕옥탄-７-온 유도체 및 세균 감염의 치료에서의 이의 용도
WO2014033561A1 (en) 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
MX2015010077A (es) 2013-02-06 2016-01-25 Astrazeneca Ab Terapia de combinacion para el tratamiento de neumonia nosocomial.
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
AU2015350128B2 (en) 2014-11-17 2019-05-16 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
CN114591223B (zh) 2016-09-16 2025-01-24 恩塔西斯治疗有限公司 β-内酰胺酶抑制剂化合物

Also Published As

Publication number Publication date
SI3630111T1 (sl) 2022-05-31
MA48743A (fr) 2020-04-08
HRP20220231T1 (hr) 2022-04-29
DK3630111T3 (en) 2022-03-14
TWI791018B (zh) 2023-02-01
AU2018266640A1 (en) 2019-11-07
MY201377A (en) 2024-02-21
CN110709081A (zh) 2020-01-17
ES2907858T3 (es) 2022-04-26
PT3630111T (pt) 2022-03-01
EP3630111B1 (en) 2021-11-24
EA201992370A1 (ru) 2020-03-10
PL3630111T3 (pl) 2022-05-23
CN110709081B (zh) 2023-09-22
EA038393B1 (ru) 2021-08-20
LT3630111T (lt) 2022-03-10
PH12019502509A1 (en) 2020-07-13
SMT202200110T1 (it) 2022-05-12
PE20200333A1 (es) 2020-02-14
IL270380B (en) 2022-06-01
US11046694B2 (en) 2021-06-29
TW201843152A (zh) 2018-12-16
MX385203B (es) 2025-03-14
JP7058322B2 (ja) 2022-04-21
CA3059773A1 (en) 2018-11-15
AU2018266640B2 (en) 2022-03-03
US20200165251A1 (en) 2020-05-28
KR102611447B1 (ko) 2023-12-06
HUE057592T2 (hu) 2022-05-28
KR20200005586A (ko) 2020-01-15
CY1125340T1 (el) 2024-02-16
JP2020519687A (ja) 2020-07-02
NZ758200A (en) 2025-12-19
SG11201909443YA (en) 2019-11-28
WO2018208769A1 (en) 2018-11-15
EP3630111A1 (en) 2020-04-08
BR112019023130A2 (pt) 2020-05-26

Similar Documents

Publication Publication Date Title
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
CL2019002204A1 (es) Compuestos inhibidores del vih.
MX2019013291A (es) Compuestos y metodos para tratar infecciones bacterianas.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2019004034A2 (es) Compuesto de piridina
MX2018005382A (es) Compuestos de biaril-monobactam y metodos de uso de los mismos para el tratamiento de infecciones bacterianas.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
CL2015001667A1 (es) Derivados de manosa para tratar infecciones bacterianas.
PE20151542A1 (es) Compuestos de tetrahidropirrolotiazina
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
DOP2017000034A (es) Compuestos de imidazopiridazina
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
CL2020001147A1 (es) Compuestos antibacterianos
UY37466A (es) N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
BR112017011980A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção bacteriana.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
CL2019000857A1 (es) Compuestos heterocíclicos y su uso para prevenir o tratar las infecciones bacterianas.
MX2018001022A (es) Antibiotico aminoglucosido novedoso efectivo contra bacterias resistentes a multiples farmacos.
BR112018011670A2 (pt) compostos antibacterianos